Compare WEAV & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | BNTC |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.2M | 405.7M |
| IPO Year | 2021 | N/A |
| Metric | WEAV | BNTC |
|---|---|---|
| Price | $6.77 | $12.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $12.20 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 1.5M | 235.3K |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,790,000.00 | N/A |
| Revenue This Year | $19.19 | N/A |
| Revenue Next Year | $15.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | N/A |
| 52 Week Low | $5.64 | $9.70 |
| 52 Week High | $17.63 | $17.15 |
| Indicator | WEAV | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 40.35 |
| Support Level | $6.23 | $12.78 |
| Resistance Level | $7.16 | $13.68 |
| Average True Range (ATR) | 0.24 | 0.75 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 70.34 | 28.74 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.